help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. suppl_2, 1-3, April 2008; doi:10.1634/theoncologist.13-S2-1
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benjamin, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benjamin, R. S.

SARC-CTOS Imaging Symposium: Introduction to the Problem from a Clinical Perspective

Robert S. Benjamin

University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA

Key Words. Sarcoma • Imaging • Response • Chemotherapy

Correspondence: Robert Benjamin, M.D., University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, Texas 77030, USA. Telephone: 713-792-3626; Fax: 713-794-1934; e-mail: rbenjami{at}mdanderson.org

Disclosure: R.B. has acted as a consultant to Novartis. No other potential conflicts of interest were reported by the author, planners, reviewers, or staff managers of this article.

Failure to correctly design clinical trials precludes effective evaluation of yield data. For instance, the Response Evaluation Criteria in Solid Tumors were developed using unidimensional measurements, while the World Health Organization criteria were based on bidimensional measurements. Attempts to compare data from the two response criteria have been problematic. There is an ongoing debate regarding the definition of what constitutes response, and there is a need to update the existing criteria. Advances in imaging techniques need to be evaluated and added into new response criteria. As sarcoma patients can derive clinical benefit from therapy without sizable tumor shrinkage, identifying other qualitative changes, such as ossification of osteosarcomas, should also be incorporated into new response criteria. This article reviews existing approaches to assess response criteria in sarcomas, and explores the role of modern imaging in the evaluation of clinical benefit.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.